Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb;28(2):e26415.
doi: 10.1002/jia2.26415.

Global prevalence of advanced HIV disease in healthcare settings: a rapid review

Affiliations
Review

Global prevalence of advanced HIV disease in healthcare settings: a rapid review

Nathan Ford et al. J Int AIDS Soc. 2025 Feb.

Abstract

Introduction: Recent studies have indicated a high enduring burden of advanced HIV disease, but estimates across regions and settings are lacking. The aim of this study was to estimate the prevalence of advanced HIV disease since 2015 among those people with CD4 measured in healthcare settings, disaggregated by age group, level of healthcare and region.

Methods: We searched MedLine via Pubmed and Hinari for studies that reported the proportion of individuals with advanced HIV disease (defined as CD4 cell count <200 cells/mm3) in healthcare settings since 2015; this search was complemented by conference abstracts and data from the International epidemiology Databases to Evaluate AIDS Consortium (IeDEA). We estimated pooled prevalence of advanced HIV disease using random-effects models and performed subgroup and sensitivity analyses to explore heterogeneity.

Results: We obtained data from 117 cohorts, representing 1,814,362 individuals from 52 countries across all six World Health Organization regions. The majority of studies (n = 83) were conducted among adults and recorded CD4 cell count among treatment naïve individuals at antiretroviral therapy start (n = 86). Studies included data reported up to 2023. The proportion of individuals with advanced HIV disease was higher in inpatient settings (44.3%, 95% CI 39.1-49.6%) compared to outpatient settings (33.5%, 95% CI 31.5-35.4%). Prevalence was similar across age groups, time since HIV diagnosis and treatment status, and highest in West and Central Africa, South-East Asia and the Eastern Mediterranean region.

Discussion: This review finds that at least a third of people presenting to healthcare settings have advanced HIV disease, with no evidence that this has changed in recent years. Screening for advanced HIV remains important to be able to direct appropriate preventive, diagnostic and therapeutic interventions to prevent progression to severe illness and death.

Conclusions: This review summarizes recent evidence of the continued high proportion of individuals who (re)present to care with advanced HIV disease. These findings underscore the urgent need to reinforce programme capacity to diagnose, prevent and treat advanced HIV disease as an essential pillar of the global AIDS response.

Keywords: CD4 cell count; advanced HIV disease; disengagement; healthcare setting; hospital; severe illness.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Study selection process.
Figure 2
Figure 2
Summary estimates of advanced HIV disease prevalence in health care settings. AHD, advanced HIV disease. Studies that reported data from both inpatient and outpatient settings not included.
Figure 3
Figure 3
Subgroup analyses. AHD, advanced HIV disease; ART, antiretroviral therapy. All analyses other than setting restricted to outpatient and mixed settings (inpatient studies dropped from analysis).

References

    1. Ghosn J, Taiwo B, Seedat S, Autran B, Katlama C. HIV. Lancet. 2018;392(10148):685–97. - PubMed
    1. Lauscher P, Hanhoff N, Valbert F, Schewe K, Koegl C, Bickel M, et al. Socio‐demographic and psycho‐social determinants of HIV late presentation in Germany ‐ results from the FindHIV study. AIDS Care. 2023;35(11):1749–59. - PubMed
    1. Leeme TB, Mine M, Lechiile K, Mulenga F, Mosepele M, Mphoyakgosi T, et al. Utility of CD4 count measurement in the era of universal antiretroviral therapy: an analysis of routine laboratory data in Botswana. HIV Med. 2021;22(1):1–10. - PMC - PubMed
    1. Osler M, Hilderbrand K, Goemaere E, Ford N, Smith M, Meintjes G, et al. The continuing burden of advanced HIV disease over 10 years of increasing antiretroviral therapy coverage in South Africa. Clin Infect Dis. 2018;66(suppl_2):S118‐S25. - PMC - PubMed
    1. Burke RM, Rickman HM, Pinto C, Ehrenkranz P, Choko A, Ford N. Reasons for disengagement from antiretroviral care in the era of “Treat All” in low‐ or middle‐income countries: a systematic review. J Int AIDS Soc. 2024;27(3):e26230. - PMC - PubMed